Non-neutralizing antibodies: Deleterious or propitious during SARS-CoV-2 infection?

被引:6
作者
Zanella, Isabella [1 ,2 ]
Degli Antoni, Melania [3 ,4 ]
Marchese, Valentina [3 ,4 ]
Castelli, Francesco [3 ,4 ]
Quiros-Roldan, Eugenia [3 ,4 ]
机构
[1] Univ Brescia, Dept Mol & Translat Med, I-25123 Brescia, Italy
[2] ASST Spedali Civili Brescia, Diagnost Dept, Cytogenet & Mol Genet Sect, Clin Chem Lab, I-25123 Brescia, Italy
[3] Univ Brescia, Dept Infect & Trop Dis, I-25123 Brescia, Italy
[4] ASST Spedali Civili Brescia, I-25123 Brescia, Italy
关键词
Antibody-dependent enhancement; Neutralizing antibodies; SARS-CoV-2; Therapies; Vaccines; DEPENDENT ENHANCEMENT; SARS-COV; VIRUS; IMMUNOPATHOLOGY; IMMUNIZATION; PROTEIN;
D O I
10.1016/j.intimp.2022.108943
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Antibody-dependent enhancement (ADE) is a complex phenomenon mediated by antibodies, frequently preexisting non-neutralizing or sub-neutralizing antibodies. In the course of infectious diseases, ADE may be responsible for worsening the clinical course of the disease by increasing the virulence of pathogens (ADE of infection) or enhancing disease severity (ADE of disease). Here we reviewed the mechanisms thought to be behind the ADE phenomenon and its potential relationship with COVID-19 severity. Since the early COVID-19 epidemics, ADE has been mentioned as a possible mechanism involved in severe COVID-19 disease and, later, as a potential risk in the case of infection after vaccination. However, current data do not support its role in disease severity, both after infection and reinfection.
引用
收藏
页数:6
相关论文
共 63 条
  • [1] Current malaria infection, previous malaria exposure, and clinical profiles and outcomes of COVID-19 in a setting of high malaria transmission: an exploratory cohort study in Uganda
    Achan, Jane
    Serwanga, Asadu
    Wanzira, Humphrey
    Kyagulanyi, Tonny
    Nuwa, Anthony
    Magumba, Godfrey
    Kusasira, Stephen
    Sewanyana, Isaac
    Tetteh, Kevin
    Drakeley, Chris
    Nakwagala, Fredrick
    Aanyu, Helen
    Opigo, Jimmy
    Hamade, Prudence
    Marasciulo, Madeleine
    Baterana, Byarugaba
    Tibenderana, James K.
    [J]. LANCET MICROBE, 2022, 3 (01): : E62 - E71
  • [2] Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)
    Agarwal, Anup
    Mukherjee, Aparna
    Kumar, Gunjan
    Chatterjee, Pranab
    Bhatnagar, Tarun
    Malhotra, Pankaj
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2020, 371
  • [3] Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus
    Agrawal, Anurodh Shankar
    Tao, Xinrong
    Algaissi, Abdullah
    Garron, Tania
    Narayanan, Krishna
    Peng, Bi-Hung
    Couch, Robert B.
    Tseng, Chien-Te K.
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (09) : 2351 - 2356
  • [4] A perspective on potential antibody-dependent enhancement of SARS-CoV-2
    Arvin, Ann M.
    Fink, Katja
    Schmid, Michael A.
    Cathcart, Andrea
    Spreafico, Roberto
    Havenar-Daughton, Colin
    Lanzavecchia, Antonio
    Corti, Davide
    Virgin, Herbert W.
    [J]. NATURE, 2020, 584 (7821) : 353 - 363
  • [5] Signaling by Antibodies: Recent Progress
    Bournazos, Stylianos
    Wang, Taia T.
    Dahan, Rony
    Maamary, Jad
    Ravetch, Jeffrey V.
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, VOL 35, 2017, 35 : 285 - 311
  • [6] Cameroni E, 2022, NATURE, V602, P664, DOI [10.1038/s41586-021-04386-2, 10.1101/2021.12.12.472269]
  • [7] The convalescent sera option for containing COVID-19
    Casadevall, Arturo
    Pirofski, Liise-Anne
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2020, 130 (04) : 1545 - 1548
  • [8] Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity
    Chakraborty, Saborni
    Gonzalez, Joseph C.
    Sievers, Benjamin L.
    Mallajosyula, Vamsee
    Chakraborty, Srijoni
    Dubey, Megha
    Ashraf, Usama
    Cheng, Bowie Yik-Ling
    Kathale, Nimish
    Tran, Kim Quyen Thi
    Scallan, Courtney
    Sinnott, Aanika
    Cassidy, Arianna
    Chen, Steven T.
    Gelbart, Terri
    Gao, Fei
    Golan, Yarden
    Ji, Xuhuai
    Kim-Schulze, Seunghee
    Prahl, Mary
    Gaw, Stephanie L.
    Gnjatic, Sacha
    Marron, Thomas U.
    Merad, Miriam
    Arunachalam, Prabhu S.
    Boyd, Scott D.
    Davis, Mark M.
    Holubar, Marisa
    Khosla, Chaitan
    Maecker, Holden T.
    Maldonado, Yvonne
    Mellins, Elizabeth D.
    Nadeau, Kari C.
    Pulendran, Bali
    Singh, Upinder
    Subramanian, Aruna
    Utz, Paul J.
    Sherwood, Robert
    Zhang, Sheng
    Jagannathan, Prasanna
    Tan, Gene S.
    Wang, Taia T.
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2022, 14 (635)
  • [9] Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus
    Dejnirattisai, Wanwisa
    Supasa, Piyada
    Wongwiwat, Wiyada
    Rouvinski, Alexander
    Barba-Spaeth, Giovanna
    Duangchinda, Thaneeya
    Sakuntabhai, Anavaj
    Cao-Lormeau, Van-Mai
    Malasit, Prida
    Rey, Felix A.
    Mongkolsapaya, Juthathip
    Screaton, Gavin R.
    [J]. NATURE IMMUNOLOGY, 2016, 17 (09) : 1102 - 1108
  • [10] IgG targeting distinct seasonal coronavirus-conserved SARS-CoV-2 spike subdomains correlates with differential COVID-19 disease outcomes
    Garrido, Jose L.
    Medina, Matias A.
    Bravo, Felipe
    McGee, Sarah
    Fuentes-Villalobos, Francisco
    Calvo, Mario
    Pinos, Yazmin
    Bowman, James W.
    Bahl, Christopher D.
    Barria, Maria Ines
    Brachman, Rebecca A.
    Alvarez, Raymond A.
    [J]. CELL REPORTS, 2022, 39 (09):